Evidence suggests dysregulation of the oxytocin system in individuals with PWS, and these neuropeptide pathways may offer promising targets for therapeutic interventions, though the mechanisms underlying this dysregulation in PWS require further investigation [74]. This evidence concerns the gene OXT and Prader-Willi syndrome.